Cytokinetics (CYTK) EVP Malik Fady Ibraham Exercises Options, Sells 3,500 Shares

What Happened
Malik Fady Ibraham, EVP Research & Development at Cytokinetics (CYTK), exercised stock options to acquire 3,500 shares and sold those 3,500 shares in an open-market transaction on 2026-09-22. The options were exercised at a strike of $7.80 per share (total cost $27,300) and the shares were sold at $68.29 each for total gross proceeds of $239,015. Net proceeds before taxes and fees were approximately $211,715.

Key Details

• Transaction date: 2026-09-22
• Option exercise (code M): 3,500 shares acquired at $7.80/share (total $27,300)
• Open-market sale (code S): 3,500 shares sold at $68.29/share (total $239,015)
• Additional derivative entry: a related option/derivative disposition for 3,500 shares reported at $0.00 (reflects conversion/exercise of the derivative)
• Shares owned after transaction: not specified in the filing
• Filing timeliness: Form filed on 2026-09-22 (same day as transactions)
• No 10b5-1 plan, tax-withholding, or other footnotes were reported in the transaction lines provided

Context
This was an option exercise followed by an immediate open-market sale (a common cashless exercise pattern). Such sales are typically routine monetizations of vested compensation rather than direct signals about company outlook; purchases tend to carry more weight for signaling insider bullishness.